VRTX has 36-month beta value of 0.42. Analysts have mixed views on the stock, with 14 analysts rating it as a “buy,” 4 as “overweight,” 14 as “hold,” and 1 as “sell.”
The public float for VRTX is 256.00M, and currently, short sellers hold a 1.88% ratio of that float. The average trading volume of VRTX on June 05, 2025 was 1.73M shares.
VRTX) stock’s latest price update
The stock of Vertex Pharmaceuticals, Inc (NASDAQ: VRTX) has decreased by -0.37 when compared to last closing price of 445.85. Despite this, the company has experienced a -0.65% fall in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-04 that NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, June 04, 2025 (GLOBE NEWSWIRE) — Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) announces the conversion of outstanding unsecured convertible debentures of the Company (the “Debentures”) pursuant to notices of conversion received from all holders of the Debentures (the “Conversion”). On January 28, 2025, the Company issued the Debentures for an aggregate principal amount of C$400,000.
VRTX’s Market Performance
Vertex Pharmaceuticals, Inc (VRTX) has seen a -0.65% fall in stock performance for the week, with a -1.30% decline in the past month and a -8.55% plunge in the past quarter. The volatility ratio for the week is 0.80%, and the volatility levels for the past 30 days are at 1.81% for VRTX. The simple moving average for the past 20 days is 1.23% for VRTX’s stock, with a -4.81% simple moving average for the past 200 days.
Analysts’ Opinion of VRTX
Leerink Partners, on the other hand, stated in their research note that they expect to see VRTX reach a price target of $503. The rating they have provided for VRTX stocks is “Market Perform” according to the report published on May 06th, 2025.
Cantor Fitzgerald gave a rating of “Overweight” to VRTX, setting the target price at $535 in the report published on April 22nd of the current year.
VRTX Trading at -5.02% from the 50-Day Moving Average
After a stumble in the market that brought VRTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -14.56% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at VRTX starting from LR 2019 Benefit Trust, who proposed sale 170 shares at the price of $447.18 back on May 21 ’25. After this action, LR 2019 Benefit Trust now owns shares of Vertex Pharmaceuticals, Inc, valued at $76,021 using the latest closing price.
SR 2019 Benefit Trust, the Director of Vertex Pharmaceuticals, Inc, proposed sale 170 shares at $447.18 during a trade that took place back on May 21 ’25, which means that SR 2019 Benefit Trust is holding shares at $76,021 based on the most recent closing price.
Stock Fundamentals for VRTX
Current profitability levels for the company are sitting at:
- -0.07 for the present operating margin
- 0.86 for the gross margin
The net margin for Vertex Pharmaceuticals, Inc stands at -0.09. The total capital return value is set at -0.04. Equity return is now at value -5.64, with -4.23 for asset returns.
Based on Vertex Pharmaceuticals, Inc (VRTX), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at -0.59. The debt to equity ratio resting at 0.1. The interest coverage ratio of the stock is -32.0.
Currently, EBITDA for the company is 486.3 million with net debt to EBITDA at 39.65. When we switch over and look at the enterprise to sales, we see a ratio of 10.02. The receivables turnover for the company is 6.15for trailing twelve months and the total asset turnover is 0.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.65.
Conclusion
To put it simply, Vertex Pharmaceuticals, Inc (VRTX) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
